Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · IEX Real-Time Price · USD
3.050
0.00 (0.00%)
At close: Mar 28, 2024, 4:00 PM
3.040
-0.010 (-0.33%)
After-hours: Mar 28, 2024, 7:03 PM EDT

Ovid Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Revenue
0.391.5208.3812.6200000
Revenue Growth (YoY)
-73.93%-99.28%1551.57%------
Gross Profit
0.391.5208.3812.6200000
Selling, General & Admin
31.0932.4337.2330.6319.2519.1415.0412.956.58
Research & Development
28.5924.6246.9463.4242.1633.7949.979.596.61
Operating Expenses
59.6757.0584.1794.0561.4152.9365.0122.5413.19
Operating Income
-59.28-55.55124.21-81.43-61.41-52.93-65.01-22.54-13.19
Other Expense / Income
-6.94-1.380.05-0.4-0.95-0.95-0.2-0.12-0.03
Pretax Income
-52.34-54.17124.16-81.04-60.46-51.98-64.81-22.41-13.16
Income Tax
001.33000000
Net Income
-52.34-54.17122.83-81.04-60.46-51.98-64.81-22.41-13.16
Shares Outstanding (Basic)
717067583925191010
Shares Outstanding (Diluted)
717068583925191010
Shares Change
0.22%3.46%16.45%49.04%59.22%27.33%96.62%1.44%-
EPS (Basic)
-0.74-0.771.78-1.39-1.54-2.11-3.35-2.28-1.36
EPS (Diluted)
-0.74-0.771.76-1.39-1.54-2.11-3.35-2.28-1.36
Free Cash Flow
-45.82-56.45118.43-51.71-51.15-45.59-31.51-17.83-5.52
Free Cash Flow Per Share
-0.65-0.801.75-0.89-1.30-1.85-1.63-1.81-0.57
Gross Margin
100.00%100.00%100.00%100.00%-----
Operating Margin
-15134.60%-3696.44%59.61%-645.40%-----
Profit Margin
-13362.17%-3604.66%58.95%-642.26%-----
Free Cash Flow Margin
-11698.19%-3756.55%56.83%-409.85%-----
Effective Tax Rate
--1.07%------
EBITDA
-50.74-52.79124.4-80.73-60.21-51.84-64.73-22.36-13.15
EBITDA Margin
-12954.57%-3512.73%59.70%-639.83%-----
Depreciation & Amortization
1.61.380.240.310.260.140.080.060.01
EBIT
-52.34-54.17124.16-81.04-60.46-51.98-64.81-22.41-13.16
EBIT Margin
-13362.17%-3604.66%59.58%-642.26%-----
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).